Cardiovascular effects of sodium glucose cotransporter 2 inhibitors

References

• American Diabetes Association 9. Cardiovascular disease and risk management Diabetes Care 2017 40 Suppl 1 S75 S87 27979896
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 9131 837 853 Erratum: Lancet. 1999;354(9178):602 9742976
   PubMed Web of Science ®Google Scholar
• Holman RR Paul SK Bethel MA Matthews DR Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 15 1577 1589 18784090
   PubMed Web of Science ®Google Scholar
• Skyler JS Bergenstal R Bonow RO Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 2009 32 1 187 192 19092168
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group Gerstein HC Miller ME Byington RP Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 2008 358 24 2545 2559 18539917
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group Patel A MacMahon S Chalmers J Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 24 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Duckworth W Abraira C Moritz T VADT Investigators Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 2009 360 2 129 139 19092145
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group Gerstein HC Miller ME Genuth S Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 2011 364 9 818 828 21366473
   PubMed Web of Science ®Google Scholar
• Giorgino F Home PD Tuomilehto J Glucose control and vascular outcomes in type 2 diabetes: is the picture clear? Diabetes Care 2016 39 Suppl 2 S187 S195 27440832
   PubMed Web of Science ®Google Scholar
• Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007 356 24 2457 2471 Erratum: N Engl J Med. 2007;357(1):100 17517853
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Guidance for industry: diabetes mellitus–evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf Accessed February 22, 2017
   Google Scholar
• Singh AK Singh R SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs Expert Rev Clin Pharmacol 2017 10 4 429 442 28121469
   PubMed Web of Science ®Google Scholar
• Scirica BM Bhatt DL Braunwald E SAVOR-TIMI 53 Steering Committee and Investigators Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N Engl J Med 2013 369 14 1317 1326 23992601
   PubMed Web of Science ®Google Scholar
• White WB Cannon CP Heller SR EXAMINE Investigators Alogliptin after acute coronary syndrome in patients with type 2 diabetes N Engl J Med 2013 369 14 1327 1335 23992602
   PubMed Web of Science ®Google Scholar
• Green JB Bethel MA Armstrong PW TECOS Study Group Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes N Engl J Med 2015 373 3 232 242 26052984
   PubMed Web of Science ®Google Scholar
• Pfeffer MA Claggett B Diaz R ELIXA Investigators Lixisenatide in patients with type 2 diabetes and acute coronary syndrome N Engl J Med 2015 373 23 2247 2257 26630143
   PubMed Web of Science ®Google Scholar
• Marso SP Daniels GH Brown-Frandsen K LEADER Steering Committee; LEADER Trial Investigators Liraglutide and cardiovascular outcomes in type 2 diabetes N Engl J Med 2016 375 4 311 322 27295427
   PubMed Web of Science ®Google Scholar
• Marso SP Bain SC Consoli A SUSTAIN-6 Investigators Semaglutide and cardiovascular outcomes in patients with type 2 diabetes N Engl J Med 2016 375 19 1834 1844 27633186
   PubMed Web of Science ®Google Scholar
• Holman RR Bethel MA Mentz RJ EXSCEL Study Group Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes N Engl J Med 2017 377 13 1228 1239 28910237
   PubMed Web of Science ®Google Scholar
• Fellner C Novel treatments target type-2 diabetes P T 2016 41 10 650 653 27757005
   PubMedGoogle Scholar
• Marso SP McGuire DK Zinman B DEVOTE Study Group Efficacy and safety of degludec versus glargine in type 2 diabetes N Engl J Med 2017 377 8 723 732 28605603
   PubMed Web of Science ®Google Scholar
• Vaccaro O Masulli M Nicolucci A Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA. IT) study group; Italian Diabetes Society Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial Lancet Diabetes Endocrinol 2017 5 11 887 897 28917544
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 7 644 657 28605608
   PubMed Web of Science ®Google Scholar
• Kosiborod M Cavender MA Fu AZ CVD-REAL Investigators and Study Group Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors) Circulation 2017 136 3 249 259 28522450
   PubMed Web of Science ®Google Scholar
• Birkeland KI Jorgensen ME Carstensen B Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis Lancet Diabetes Endocrinol 2017 5 9 709 717 28781064
   PubMed Web of Science ®Google Scholar
• Marx N Rosenstock J Kahn SE Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®) Diab Vasc Dis Res 2015 12 3 164 174 25780262
   PubMed Web of Science ®Google Scholar
• Jardine MJ Mahaffey KW Neal B CREDENCE study investigators The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics Am J Nephrol 2017 46 6 462 472 29253846
   PubMed Web of Science ®Google Scholar
• Novo Nordisk US Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events Available from: http://press.novonordisk-us.com/2017-08-25-Victoza-R-liraglutide-is-approved-in-the-US-as-the-only-type-2-diabetes-treatment-indicated-to-reduce-the-risk-of-three-major-adverse-cardiovascular-events Accessed October 11, 2017
   Google Scholar
• CardioBrief Clinical trial expert’s deep dive into the important new liraglutide trial Available from: http://www.cardiobrief.org/2016/06/13/clinical-trial-experts-deep-dive-into-the-important-new-liraglutide-trial/ Accessed October 11, 2017
   Google Scholar
• Abdul-Ghani M Del Prato S Chilton R DeFronzo RA SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study Diabetes Care 2016 39 5 717 725 27208375
   PubMed Web of Science ®Google Scholar
• Pitt B Remme W Zannad F Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 14 1309 1321 12668699
   PubMed Web of Science ®Google Scholar
• Fitchett D Zinman B Wanner C EMPA-REG OUTCOME® trial investigators Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA- REG OUTCOME® trial Eur Heart J 2016 37 19 1526 1534 26819227
   PubMed Web of Science ®Google Scholar
• Raz I Cahn A Heart failure: SGLT2 inhibitors and heart failure – clinical implications Nat Rev Cardiol 2016 13 4 185 186 26961066
   PubMed Web of Science ®Google Scholar
• Baartscheer A Schumacher CA Wust RC Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits Diabetologia 2017 60 3 568 573 27752710
   PubMed Web of Science ®Google Scholar
• Verma S Garg A Yan AT Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016 39 12 e212 e213 27679584
   PubMed Web of Science ®Google Scholar
• Tucker ME CANVAS: experts spar on canagliflozin risk/benefit in diabetes Available from: http://www.medscape.com/viewarticle/881719 Accessed July 10, 2017
   Google Scholar
• Schilsky RL Finding the evidence in real-world evidence: moving from data to information to knowledge J Am Coll Surg 2017 224 1 1 7 27989954
   PubMed Web of Science ®Google Scholar
• Fitchett D SGLT2 inhibitors in the real world: too good to be true? Lancet Diabetes Endocrinol 2017 5 9 673 675 28781063
   PubMed Web of Science ®Google Scholar
• Vallon V The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus Annu Rev Med 2015 66 255 270 25341005
   PubMed Web of Science ®Google Scholar
• Vestri S Okamoto MM de Freitas HS Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat J Membr Biol 2001 182 2 105 112 11447502
   PubMed Web of Science ®Google Scholar
• Tabatabai NM Sharma M Blumenthal SS Petering DH Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats Diabetes Res Clin Pract 2009 83 1 e27 e30 19095325
   PubMedGoogle Scholar
• STEGLATRO™ (ertugliflozin) tablets, for oral use [prescribing information] Kenilworth, NJ Merck Sharp & Dohme Corp 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf Accessed January 3, 2018
   Google Scholar
• Storgaard H Gluud LL Bennett C Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis PLoS One 2016 11 11 e0166125 27835680
   PubMed Web of Science ®Google Scholar
• Scheen AJ Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: a critical analysis Diabetes Metab 2016 42 2 71 76 26856453
   PubMed Web of Science ®Google Scholar
• Heise T Seewaldt-Becker E Macha S Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks’ treatment with empagliflozin once daily in patients with type 2 diabetes Diabetes Obes Metab 2013 15 7 613 621 23356556
   PubMed Web of Science ®Google Scholar
• Cefalu WT Leiter LA Yoon KH Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 9896 941 950 23850055
   PubMed Web of Science ®Google Scholar
• Bolinder J Ljunggren Ö Johansson L Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin Diabetes Obes Metab 2014 16 2 159 169 23906445
   PubMed Web of Science ®Google Scholar
• Ridderstråle M Andersen KR Zeller C Kim G Woerle HJ Broedl UC EMPA-REG H2H-SU trial investigators Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial Lancet Diabetes Endocrinol 2014 2 9 691 700 24948511
   PubMed Web of Science ®Google Scholar
• Ferrannini E Baldi S Frascerra S Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes Diabetes 2016 65 5 1190 1195 26861783
   PubMed Web of Science ®Google Scholar
• Després JP Lemieux I Abdominal obesity and metabolic syndrome Nature 2006 444 7121 881 887 17167477
   PubMed Web of Science ®Google Scholar
• Lee MJ Wu Y Fried SK Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications Mol Aspects Med 2013 34 1 1 11 23068073
   PubMed Web of Science ®Google Scholar
• Daniele G Xiong J Solis-Herrera C Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes Diabetes Care 2016 39 11 2036 2041 27561923
   PubMed Web of Science ®Google Scholar
• Cahill GFJr Veech RL Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003 114 149 161 discussion 162–163 12813917
   PubMedGoogle Scholar
• Sato K Kashiwaya Y Keon CA Insulin, ketone bodies, and mitochondrial energy transduction FASEB J 1995 9 8 651 658 7768357
   PubMed Web of Science ®Google Scholar
• Tahara A Kurosaki E Yokono M Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats J Pharm Pharmacol 2014 66 7 975 987 24533859
   PubMed Web of Science ®Google Scholar
• Mudaliar S Alloju S Henry RR Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis Diabetes Care 2016 39 7 1115 1122 27289124
   PubMed Web of Science ®Google Scholar
• Ferrannini E Mark M Mayoux E CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis Diabetes Care 2016 39 7 1108 1114 27289126
   PubMed Web of Science ®Google Scholar
• Xiong W Xiao MY Zhang M Chang F Efficacy and safety of canagliflozin in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Medicine (Baltimore) 2016 95 48 e5473 27902600
   PubMed Web of Science ®Google Scholar
• Kohler S Zeller C Iliev H Kaspers S Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials Adv Ther 2017 34 7 1707 1726 28631216
   PubMed Web of Science ®Google Scholar
• Haas B Eckstein N Pfeifer V Mayer P Hass MDS Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin Nutr Diabetes 2014 4 11 e143 25365416
   PubMed Web of Science ®Google Scholar
• Briand F Mayoux E Brousseau E Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism Diabetes 2016 65 7 2032 2038 27207551
   PubMed Web of Science ®Google Scholar
• Wu AH Gladden JD Ahmed M Ahmed A Filippatos G Relation of serum uric acid to cardiovascular disease Int J Cardiol 2016 213 4 7 26341316
   PubMed Web of Science ®Google Scholar
• Cheeseman C Solute carrier family 2, member 9 and uric acid homeostasis Curr Opin Nephrol Hypertens 2009 18 5 428 432 19593129
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Zinman B Wanner C SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials Diab Vasc Dis Res 2015 12 2 90 100 25589482
   PubMed Web of Science ®Google Scholar
• Tikkanen I Chilton R Johansen OE Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension Curr Opin Nephrol Hypertens 2016 25 2 81 86 26808705
   PubMed Web of Science ®Google Scholar
• Tikkanen I Narko K Zeller C EMPA-REG BP Investigators Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension Diabetes Care 2015 38 3 420 428 25271206
   PubMed Web of Science ®Google Scholar
• Townsend RR Machin I Ren J Reductions in mean 24-hour ambulatory blood pressure after 6-week treatment with canagliflozin in patients with type 2 diabetes mellitus and hypertension J Clin Hypertens (Greenwich) 2016 18 1 43 52 26663712
   PubMed Web of Science ®Google Scholar
• Weber MA Mansfield TA Cain VA Iqbal N Parikh S Ptaszynska A Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study Lancet Diabetes Endocrinol 2016 4 3 211 220 26620248
   PubMed Web of Science ®Google Scholar
• Cook NR Cohen J Hebert PR Taylor JO Hennekens CH Implications of small reductions in diastolic blood pressure for primary prevention Arch Intern Med 1995 155 7 701 709 7695458
   PubMed Web of Science ®Google Scholar
• Hardy ST Loehr LR Butler KR Reducing the blood pressure- related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control J Am Heart Assoc 2015 4 10 e002276 26508742
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ de Zeeuw D Wie L Leslie B List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 2013 15 9 853 862 23668478
   PubMed Web of Science ®Google Scholar
• Kimura G Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis J Am Soc Hypertens 2016 10 3 271 278 26874564
   PubMed Web of Science ®Google Scholar
• Cefalu WT Stenlöf K Leiter LA Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes Diabetologia 2015 58 6 1183 1187 25813214
   PubMed Web of Science ®Google Scholar
• Cherney DZ Perkins BA Soleymanlou N The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus Cardiovasc Diabetol 2014 13 28 24475922
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Zinman B Fitchett D How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial Diabetes Care 2018 41 2 356 363 29203583
   PubMed Web of Science ®Google Scholar
• Scheen AJ Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: comparison with classic diuretics Diabetes Metab 2016 42 4 224 233 27291329
   PubMed Web of Science ®Google Scholar
• Marx N McGuire DK Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus Eur Heart J 2016 37 42 3192 3200 27153861
   PubMed Web of Science ®Google Scholar
• Mudaliar S Polidori D Zambrowicz B Henry RR Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside Diabetes Care 2015 38 12 2344 2353 26604280
   PubMed Web of Science ®Google Scholar
• Sano M Takei M Shiraishi Y Suzuki Y Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys J Clin Med Res 2016 8 12 844 847 27829948
   PubMedGoogle Scholar
• Cherney DZ Perkins BA Soleymanlou N Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 2014 129 5 587 597 24334175
   PubMed Web of Science ®Google Scholar
• Muskiet MH van Raalte DH van Bommel EJ Smits MM Tonneijck L Understanding EMPA-REG OUTCOME Lancet Diabetes Endocrinol 2015 3 12 928 929 26590679
   PubMed Web of Science ®Google Scholar
• Wang Y Katzmarzyk PT Horswell R Zhao W Johnson J Hu G Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes Kidney Int 2014 85 5 1192 1199 24107845
   PubMed Web of Science ®Google Scholar
• Wanner C Inzucchi SE Lachin JM EMPA-REG OUTCOME Investigators Empagliflozin and progression of kidney disease in type 2 diabetes N Engl J Med 2016 375 4 323 334 27299675
   PubMed Web of Science ®Google Scholar
• Heerspink HJ Desai M Jardine M Balis D Meininger G Perkovic V Canagliflozin slows progression of renal function decline independently of glycemic effects J Am Soc Nephrol 2017 28 1 368 375 27539604
   PubMed Web of Science ®Google Scholar
• Ross R Atherosclerosis–an inflammatory disease N Engl J Med 1999 340 2 115 126 9887164
   PubMed Web of Science ®Google Scholar
• Beckman JA Creager MA Libby P Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 2002 287 19 2570 2581 12020339
   PubMed Web of Science ®Google Scholar
• Tahara A Kurosaki E Yokono M Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Eur J Pharmacol 2013 715 1–3 246 255 23707905
   PubMed Web of Science ®Google Scholar
• Osorio H Coronel I Arellano A Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats Oxid Med Cell Longev 2012 2012 542042 23227274
   PubMed Web of Science ®Google Scholar
• Salim HM Fukuda D Yagi S Soeki T Shimabukuro M Sata M Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse Front Cardiovasc Med 2016 3 43 27833913
   PubMed Web of Science ®Google Scholar
• Larsen EL Cejvanovic V Kjaer LK The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial BMJ Open 2017 7 5 e014728
   PubMed Web of Science ®Google Scholar
• Tabit CE Chung WB Hamburg NM Vita JA Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications Rev Endocr Metab Disord 2010 11 1 61 74 20186491
   PubMed Web of Science ®Google Scholar
• Goligorsky MS Chen J Brodsky S Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide Hypertension 2001 37 2 Pt 2 744 748 11230367
   PubMed Web of Science ®Google Scholar
• Chu S Bohlen HG High concentration of glucose inhibits glomerular endothelial eNOS through a PKC mechanism Am J Physiol Renal Physiol 2004 287 F384 F392 15140758
   PubMed Web of Science ®Google Scholar
• Jones BJ Tan T Bloom SR Minireview: glucagon in stress and energy homeostasis Endocrinology 2012 153 3 1049 1054 22294753
   PubMed Web of Science ®Google Scholar
• Ferrannini E Muscelli E Frascerra S Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients J Clin Invest 2014 124 2 499 508 24463454
   PubMed Web of Science ®Google Scholar
• Bonner C Kerr-Conte J Gmyr V Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion Nat Med 2015 21 5 512 517 25894829
   PubMed Web of Science ®Google Scholar
• Ceriello A Genovese S Mannucci E Gronda E Glucagon and heart in type 2 diabetes: new perspectives Cardiovasc Diabetol 2016 15 1 123 27568179
   PubMed Web of Science ®Google Scholar
• Wright EM Loo DD Hirayama BA Biology of human sodium glucose transporters Physiol Rev 2011 91 2 733 794 21527736
   PubMed Web of Science ®Google Scholar
• Cariou B Charbonnel B Sotagliflozin as a potential treatment for type 2 diabetes mellitus Expert Opin Investig Drugs 2015 24 12 1647 1656
   PubMed Web of Science ®Google Scholar
• Kashiwagi Y Nagoshi T Yoshino T Expression of SGLT1 in human hearts and impairment of cardiac glucose uptake by phlorizin during ischemia-reperfusion injury in mice PLoS One 2015 10 6 e0130605 26121582
   PubMed Web of Science ®Google Scholar
• Grempler R Thomas L Eckhardt M Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes Metab 2012 14 1 83 90 21985634
   PubMed Web of Science ®Google Scholar
• Tanaka A Shimabukuro M Okada Y EMBLEM Trial Investigators Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial Cardiovasc Diabetol 2017 16 1 48 28403850
   PubMed Web of Science ®Google Scholar